GB814491A - Lipid mobiliser - Google Patents

Lipid mobiliser

Info

Publication number
GB814491A
GB814491A GB38506/56A GB3850656A GB814491A GB 814491 A GB814491 A GB 814491A GB 38506/56 A GB38506/56 A GB 38506/56A GB 3850656 A GB3850656 A GB 3850656A GB 814491 A GB814491 A GB 814491A
Authority
GB
United Kingdom
Prior art keywords
lipid
mobilizer
specified
free
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB38506/56A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of GB814491A publication Critical patent/GB814491A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A lipid mobilizer may be obtained by dialysing the plasma of stressed mammals and freeze drying the dialysate. Specified nammals are rat, dog, man and preferably horse. Specified stresses are subjection to sub-normal temperature above 0 DEG C., administration of a convulsant drug such as diisopropylfluorophosphate or cholic acid, injection of protamine, anti-kidney serum or preferably cortisone. The lipid mobilizer may be dissolved in pyrogen-free aqueous medium for parenteral administration. The lipid mobilizer has the property when injected into animals of producing hyperlipemia, hyperphagia and depleting fat deposits in the body. It is a non-protein solid, freely soluble in water and physiological salt solution, less soluble in methanol and insoluble in 95 per cent ethanol or acetone, non-extractable by ether from acid or alkaline aqueous solutions, dialysable through semi-permeable membranes against water, comprising a low molecular weight polypeptide as the active ingredient, free of steroids and giving a positive ninhydrin reaction.
GB38506/56A 1956-01-17 1956-12-18 Lipid mobiliser Expired GB814491A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US814491XA 1956-01-17 1956-01-17

Publications (1)

Publication Number Publication Date
GB814491A true GB814491A (en) 1959-06-03

Family

ID=22164234

Family Applications (1)

Application Number Title Priority Date Filing Date
GB38506/56A Expired GB814491A (en) 1956-01-17 1956-12-18 Lipid mobiliser

Country Status (1)

Country Link
GB (1) GB814491A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758724A1 (en) * 1997-01-24 1998-07-31 Javenech Controlling cellulite and fat deposition
US9863699B2 (en) 2014-06-09 2018-01-09 Terumo Bct, Inc. Lyophilization
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11994343B2 (en) 2023-07-11 2024-05-28 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758724A1 (en) * 1997-01-24 1998-07-31 Javenech Controlling cellulite and fat deposition
US9863699B2 (en) 2014-06-09 2018-01-09 Terumo Bct, Inc. Lyophilization
US10539367B2 (en) 2014-06-09 2020-01-21 Terumo Bct, Inc. Lyophilization
US10969171B2 (en) 2014-06-09 2021-04-06 Terumo Bct, Inc. Lyophilization
US10976105B2 (en) 2014-06-09 2021-04-13 Terumo Bct, Inc. Lyophilization
US11067336B2 (en) 2014-06-09 2021-07-20 Terumo Bct, Inc. Lyophilization
US11137206B2 (en) 2014-06-09 2021-10-05 Terumo Bct, Inc. Lyophilization
US11634257B2 (en) 2017-10-09 2023-04-25 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11609043B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US11609042B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11740019B2 (en) 2019-03-14 2023-08-29 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11747082B2 (en) 2019-03-14 2023-09-05 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11815311B2 (en) 2019-03-14 2023-11-14 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US11994343B2 (en) 2023-07-11 2024-05-28 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use

Similar Documents

Publication Publication Date Title
Permin Properties of the fibrinokinase-fibrinolysin system
Heilman et al. THE INFLUENCE OF 11-DEHYDR0-17-HYDR0XYCORTICOSTERONE (COMPOUND E) ON THE GROWTH OF A MALIGNANT TUMOR IN THE MOUSE1
Feldberg et al. The formation of lysocithin and of a muscle-stimulating substance by snake venoms
Fink et al. PLASMA PROTEIN METABOLISM—NORMAL AND ASSOCIATED WITH SHOCK: OBSERVATIONS USING PROTEIN LABELED BY HEAVY NITROGEN IN LYSINE
BERCU et al. Antidiuretic action of the urine of patients in cardiac failure
Lorenz et al. Histamine in the pig: determination, distribution, release and pharmacological actions
US2162863A (en) Stable products shortening the bleeding period
Nasset Enterocrinin, a hormone which excites the glands of the small intestine
GB814491A (en) Lipid mobiliser
US3200110A (en) Process for the preparation of laminarin sulfates
US2488565A (en) Preparation of hyaluronidase
Menkin Studies on inflammation: Xvi. On the formation of a chemotactic substance by enzymatic action
Davies et al. Observations on the preparation, properties and source of the parathyroid hormone. Part I
Walser et al. 522 The effect of diuresis and diuretics upon the renal tubular transport of alkaline earth
SCHNITKER et al. Presence of digitalis in body fluids of digitalized patients
GB721312A (en) Improvements in or relating to the formation of fibrous protein from solutions of collagen
ES358119A1 (en) Cosmetic therapeutic preparations containing animal organ extracts
Houssay et al. Renin in Experimental Hypertension
Gagliardino et al. Relationship between differential responsiveness of pancreatic β cells and the circadian variation of serum immunoreactive insulin levels
Nadal et al. Inhibition of rat hepatocyte multiplication by serum and liver factors: Physiological development and experimental induction
Ovcharov et al. Anti-inflammatory effects of apamin
Cullumbine Leukotaxine and histamine
Agar et al. The inhibition of the intestinal absorption of an amino acid by chlortetracycline
GB974910A (en) Polypeptide growth promoting agent for animals
Despopoulos 521 Renal transport of organic anions: a unifying hypothesis